© 2017


  • Aung Naing
  • Joud Hajjar
  • Highlights the significant developments in the field of immuno-oncology to inform the scientific community

  • Summarizes diverse immunotherapeutic approaches for management of cancer to update professionals with the latest

  • Presents challenges in the emerging field of immunotherapy to prompt further translational research

  • Editors and authors are nationally and internationally renowned experts in the field of immunology/oncology


Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 995)

Table of contents

  1. Front Matter
    Pages i-v
  2. Bettzy Stephen, Joud Hajjar
    Pages 1-31
  3. Jonathan E. Schoenhals, Tijana Skrepnik, Ugur Selek, Maria A. Cortez, Ailin Li, James W. Welsh
    Pages 53-71
  4. Lucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, Farhad Ravandi, Padmanee Sharma, Naval Daver
    Pages 73-95
  5. Christian Rolfo, Christian Caglevic, Mariacarmela Santarpia, Antonio Araujo, Elisa Giovannetti, Carolina Diaz Gallardo et al.
    Pages 97-125
  6. Peter M. Anderson
    Pages 127-140
  7. Yousra Eleneen, Rivka R. Colen
    Pages 141-153
  8. Noha Abdel-Wahab, Anas Alshawa, Maria E. Suarez-Almazor
    Pages 155-174
  9. Anisha B. Patel, Omar Pacha
    Pages 175-184

About this book


In the last decade, immunotherapy has revolutionized the practice of medicine in the field of oncology. This book, Immunotherapy, highlights the immunotherapeutic approaches currently in use and strategies to overcome the associated challenges. As comprehensive knowledge of basic immunology in the context of tumor biology is required to move further along the line of development in translational science, this book provides an overview of the cellular components of the immune system that interact with each other to provide a successful immune response.

Immunotherapy offers promising antitumor activity across multiple cancer types as it does not attack the tumor but primarily revitalizes a suppressed immune system. It is beyond the scope of this book to discuss the immunotherapeutic approaches across the tumor board. However, the book features the role of immune-oncology in acute myeloid leukemia, non-small cell lung cancer, and sarcomas to showcase the recent advances in the management of cancer broadly classified as hematological malignancies, solid tumors, and tumors arising in the connective tissue. The book also discusses alternative formulations and combinatorial approaches to enhance the therapeutic index of these agents.

As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. In this book, we discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies, and clinical implications. The book also outlines how recent advances in medical imaging technology have the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring. Importantly, the book attempts to increase the awareness to immune related adverse events and the need for aggressive and judicious management of toxicities to improve treatment outcomes in patients on immunotherapy

In short, this book provides a broad understanding of immunotherapy and ways to leverage the immune system to make inroads in the fight against cancer.


Immunotherapy Translational cancer immunology Vaccine IL-10 ImmunoOncology

Editors and affiliations

  • Aung Naing
    • 1
  • Joud Hajjar
    • 2
  1. 1.MD Anderson Cancer CenterUniversity of TexasHoustonUSA
  2. 2.Baylor College of Medicine-Texas Children’s HospitalHoustonUSA

About the editors

Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing’s research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.

Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.

Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.

Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.

Bibliographic information

  • Book Title Immunotherapy
  • Editors Aung Naing
    Joud Hajjar
  • Series Title Advances in Experimental Medicine and Biology
  • Series Abbreviated Title Adv Exp Med Biol
  • DOI
  • Copyright Information Springer International Publishing AG 2017
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-53155-7
  • eBook ISBN 978-3-319-53156-4
  • Series ISSN 0065-2598
  • Series E-ISSN 2214-8019
  • Edition Number 1
  • Number of Pages V, 184
  • Number of Illustrations 17 b/w illustrations, 0 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods